Breakeven On The Horizon For Redcare Pharmacy NV (ETR:RDC)

With the business potentially at an important milestone, we thought we'd take a closer look at Redcare Pharmacy NV's (ETR:RDC) future prospects. Redcare Pharmacy NV operates in online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. The €1.8b market-cap company posted a loss in its most recent financial year of €45m and a latest trailing-twelve-month loss of €48m leading to an even wider gap between loss and breakeven. Many investors are wondering about the rate at which Redcare Pharmacy will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Consensus from 10 of the German Consumer Retailing analysts is that Redcare Pharmacy is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of €25m in 2026. So, the company is predicted to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 53% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

We're not going to go through company-specific developments for Redcare Pharmacy given that this is a high-level summary, but, take into account that generally a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for Redcare Pharmacy

Before we wrap up, there’s one issue worth mentioning. Redcare Pharmacy currently has a relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in Redcare Pharmacy's case is 50%. A higher level of debt requires more stringent capital management which increases the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Redcare Pharmacy to cover in one brief article, but the key fundamentals for the company can all be found in one place – Redcare Pharmacy's company page on Simply Wall St. We've also put together a list of relevant factors you should further research:

1. Valuation: What is Redcare Pharmacy worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Redcare Pharmacy is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Redcare Pharmacy’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.